5,080 runners from all seven continents joined the 12th NCT Run. Together, the active members of the global online community collected 70,000 euros in donations, which will benefit innovative projects for applied cancer research at the National Center for Tumor Diseases (NCT) Heidelberg.
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD).
In 2023, the NCT Run motivated a worldwide online community to move again. 5,080 runners joined for the good cause of the NCT run between July 7 and 9 at 1,000 starting locations on all seven continents. A total of 66,500 kilometers were run together.
Dirk Jäger, Managing Director at the NCT Heidelberg and head of the department of Medical Oncology at Heidelberg University Hospital (UKHD), says: "Many thanks to all participants. Through their participation and especially their donations, they significantly support the work at the NCT Heidelberg. This is a great commitment for the benefit of our patients."
Due to the outstanding commitment on a scorching running weekend, the main sponsor, SAP, rewards the team performance of all runners with the total offered donation sum of 30,000 euros, although the ambitious goal of 100,000 joint running kilometers was not reached. Through further donations, the NCT Run's fundraising total comes together to 70,000 euros. The donations will benefit innovative projects for applied cancer research at the NCT Heidelberg.
Stefan Fröhling, Managing Director at the NCT Heidelberg and head of the division of Translational Medical Oncology at the German Cancer Research Center (DKFZ), says: "The fact that the NCT Run has now once again inspired active people on all seven continents is a great thing. The NCT Run has a triple positive impact, as it gets people to move, draws attention to innovative applied cancer research, and raises funds for this important mission."
An image of the press release is available free of charge on the Internet at:
https://www.nct-heidelberg.de/fileadmin/media/nct-heidelberg/news/pressemitteilungen/NCT-Lauf_2023_Zielband.jpg
Image description:
Joy at the finish line of the NCT run: a total of 5080 participants worldwide raised 70,000 euros in donations, here a group of alumni of the German Cancer Research Center (DKFZ).
Note on the use of images for press releases:
Use is free of charge. The NCT Heidelberg permits one-time use in connection with reporting on the subject of the press release. Please quote the copyright " NCT Heidelberg" as photo credit. The image material may only be passed on to third parties after prior consultation with NCT Communications (Phone: +49 6221 42-1755, e-mail: martin.staiger@nct-heidelberg.de). Use for commercial purposes is prohibited.
Contact for the press:
Dr. Martin Staiger
National Center for Tumor Diseases (NCT) Heidelberg
Communication and Events
Im Neuenheimer Feld 460
69120 Heidelberg
Phone: +49 6221 42-1755
E-mail: martin.staiger@nct-heidelberg.de
www.nct-heidelberg.de
Dr. Sibylle Kohlstädt
German Cancer Research Center (DKFZ)
Strategic Communications and Public Relations
Im Neuenheimer Feld 280
69120 Heidelberg
Phone: +49 6221 42-2843
Fax: +49 6221 42-2968
E-mail: s.kohlstaedt@dkfz.de
www.dkfz.de
Julia Bird
Comm. Head of Corporate Communications, Comm. Press Spokeswoman
Heidelberg University Hospital and Medical Faculty of Heidelberg University
Press and Public Relations
Im Neuenheimer Feld 672
69120 Heidelberg
Phone: +49 6221 56-7071
Fax: +49 6221 56-4544
E-mail: presse@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de
The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.
German Cancer Research Center (DKFZ)
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
- National Center for Tumor Diseases (NCT, 6 sites)
- German Cancer Consortium (DKTK, 8 sites)
- Hopp Children's Cancer Center (KiTZ) Heidelberg
- Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
- DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
- National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
Heidelberg University Hospital and Faculty of Medicine: Internationally Renowned Patient Care, Research and Teaching
Heidelberg University Hospital (Universitätsklinikum Heidelberg, UKHD) is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University (Medizinische Fakultät Heidelberg, MFHD) belongs to the internationally renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. Heidelberg University Hospital and the Medical Faculty of Heidelberg University employs around 14.500 employees and is committed to providing trainings and qualifications. Every year, around 86,000 patients and more than 1.100.000 outpatient cases are treated in more than 50 clinical departments with almost 2.500 beds. Together with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the German Cancer Aid, the UKHD established the first National Center for Tumor Diseases (NCT) in Heidelberg. The goal is to provide care at the highest level as an oncology center of excellence and to rapidly transfer promising approaches from cancer research to the hospital. In addition, the UKHD operates in partnership with the DKFZ and the University of Heidelberg the Hopp Children’s Cancer center Heidelberg (KiTZ), a unique and nationally known therapy and research center for oncological and hematological diseases in children and adolescents. The Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany. Currently, there are about 4.000 future physicians studying in Heidelberg.